Life | Brand & Name Creation Personalized For Pharma & Life Sciences: Consistent with our work in the other major verticals, we collaborate with pharmaceutical and life science clients to offer dynamic, proven leadership to resolve the challenge of brand or name creation. However, as our portfolio of breakthrough pharma brands can attest, we are noted for innovation and as pioneers in the highly specialized practice of creating successful pharmaceutical trademarks.

The present state of pharmaceutical trademark development reflects the importance of initiating the process early and the rigorous pursuit of a diverse spectrum of names.

We have a proven record of introducing industry-wide best practices for name ideation, creation, filtration and assessment to deliver names which can attain registration status combined with FDA, EMA and other major market agency approvals. These best practices reflect 20 years of pharmaceutical branding and naming experience and 100+ FDA and/or EMA approved trademarks and are formalized within our branding and naming methodologies and related framework: 

We recognize the importance of strategic insight to drive the creation of meaningful brands and build internal consensus. Creating a trademark is a challenge under any circumstance. Given that the process of pharmaceutical trademark development may begin as early as the end of Phase 1, the long lead time combined with added uncertainties creates a complex challenge.

In combination with our framework, we tailor universal brand and name creation techniques such as 'brandforecasting' and 'namecrafting' to address specific pharmaceutical and life science considerations and constraints. Exploring the preliminary fabric of brand promise, essence and positioning for a given opportunity, we facilitate the consideration of objective measures such as audience segmentation, tone and messaging to manage the subjective first impressions that may accompany a challenging, yet potentially breakthrough, pharma brand name candidate.

We increase the stringency of our filters with every step, leading to our 'nameprojection' research model to identify the potential of drug name confusion and to forecast the likelihood of regulatory approval. As expertise in navigating the challenges of regulatory approval represents the primary consideration in choosing a consultant or agency, every name recommendation is reviewed by Clement Galluccio, who launched and served for 13 years as the MD of rxmark, the analytics subsidiary of Wood Worldwide/Interbrand Wood Healthcare. Clement was an invited speaker at the FDA Public Meetings to discuss methodologies for assessing proposed drug names, a reflection of his influential role as manager of the very first comprehensive research model to address the issue of medication error.

The result is a balance of maximizing the pharma brand opportunity while minimizing the potential damage of unforeseen trademark conflicts including the risk of regulatory rejection.